SCHEMBL849912

SCHEMBL849912

CN(CCOS(C)(=O)=O)C(=O)OC(C)(C)C

nearest known ligand 0.42

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 1/20 0.38
USP2 O75604 1/20 0.38
ALDH1A1 P00352 1/20 0.38
LMNA P02545 1/20 0.38
MMP9 P14780 1/20 0.38
ALOX15 P16050 1/20 0.38
TSHR P16473 1/20 0.38
PDK2 Q15119 1/20 0.37
CA14 Q9ULX7 2/20 0.35
CA12 O43570 1/20 0.35
CA1 P00915 1/20 0.35
CA7 P43166 1/20 0.35
HDAC6 Q9UBN7 2/20 0.32
HDAC1 Q13547 1/20 0.32
HDAC2 Q92769 1/20 0.32
GBA1 P04062 1/20 0.31
METAP2 P50579 1/20 0.31
KAT6A Q92794 1/20 0.31
KAT5 Q92993 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16379403 0.91 PDK2 (0.34) KDM4EUSP2ALDH1A1LMNAMMP9
SCHEMBL21070068 0.91 PDK2 (0.34) KDM4EUSP2ALDH1A1LMNAMMP9
SCHEMBL19585770 0.91 PDK2 (0.34) KDM4EUSP2ALDH1A1LMNAMMP9
SCHEMBL381079 0.90 KDM4E (0.44) KDM4EUSP2ALDH1A1LMNAMMP9
SCHEMBL8130163 0.89 KDM4E (0.47) KDM4EUSP2ALDH1A1LMNAMMP9
SCHEMBL1109837 0.87 LMNA (0.46) KDM4EUSP2ALDH1A1LMNAMMP9
SCHEMBL1924375 0.87 LMNA (0.46) KDM4EUSP2ALDH1A1LMNAMMP9
SCHEMBL27160377 0.87 LMNA (0.46) KDM4EUSP2ALDH1A1LMNAMMP9
SCHEMBL17998104 0.87 LMNA (0.46) KDM4EUSP2ALDH1A1LMNAMMP9
SCHEMBL21537283 0.87 CA12 (0.33) KDM4EUSP2ALDH1A1LMNAMMP9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 80 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4168399-B1 COMPOUNDS AND THEIR USES AS MIF INHIBITORS NANJING IMMUNOPHAGE BIOMEDICAL CO LTD (CN) 2026-04-01 EP disclosed
EP-3826722-B1 ISOQUINOLINE COMPOUNDS AND USES THEREOF HOFFMANN LA ROCHE (CH) 2026-02-18 EP disclosed
US-20260034140-A1 MODULATORS OF RHO-ASSOCIATED PROTEIN KINASE REDX PHARMA LTD (GB) 2026-02-05 US disclosed
US-12453734-B2 Modulators of rho-associated protein kinase REDX PHARMA LIMITED (GB) 2025-10-28 US disclosed
US-12378249-B2 Isoquinoline compounds and uses thereof GENENTECH, INC. (US) 2025-08-05 US disclosed
US-12281119-B2 Imidazo[2,1-f][1,2,4]triazin-4-amine derivatives as TLR7 agonist BEIGENE, LTD. (KY) 2025-04-22 US disclosed
WO-2025051148-A1 NITROGEN-CONTAINING HETEROARYL COMPOUND, AND PREPARATION METHOD THEREFOR AND USE THEREOF 北京鞍石生物科技股份有限公司 2025-03-13 WO disclosed
WO-2024226890-A1 PYRAZOLE 3H-IMIDAZO(4,5-B)PYRIDINE COMPOUNDS AND USES THEREOF Verge Analytics, Inc. (US) 2024-10-31 WO disclosed
US-20240216386-A1 MODULATORS OF RHO-ASSOCIATED PROTEIN KINASE REDX PHARMA LIMITED (GB) 2024-07-04 US disclosed
US-20240216386-A1 MODULATORS OF RHO-ASSOCIATED PROTEIN KINASE REDX PHARMA LIMITED (GB) 2024-07-04 US disclosed
EP-1661904-A1 NOVEL AZALIDE AND AZALACTAM DERIVATIVES AND PROCESS FOR THE PRODUCTION OF THE SAME MEIJI SEIKA KAISHA LTD. (JP) 2006-05-31 EP disclosed
US-20050119489-A1 4-Sulfide/sulfoxide/sulfonyl-1h-pyrazolyl derivative compounds, for use in diseases associated with the 5-ht2c receptor BAYER HEALTHCARE AG (DE) 2005-06-02 US disclosed
EP-1220856-B1 PYRAZOLO[4,3-D]PYRIMIDINE DERIVATIVES PFIZER LTD (GB) 2004-12-08 EP disclosed
EP-1465872-A1 4-SULFIDE/SULFOXIDE/SULFONYL-1H-PYRAZOLYL DERIVATIVE COMPOUNDS, FOR USE IN DISEASES ASSOCIATED WITH THE 5-HT2C RECEPTOR Bayer Pharmaceuticals Corporation (US) 2004-10-13 EP disclosed
US-20040152712-A1 Pharmaceutically active compounds PFIZER INC. 2004-08-05 US disclosed
US-6677335-B1 PYRAZOLO(4,3-D)PYRIMIDIN-7-ONE DERIVATIVES; CYCLIC GUANOSINE 3',5'-MONOPHOSPHATE PHOSPHODIESTERASE INHIBITORS; SEXUAL AND UROGENITAL DISORDERS PFIZER INC 2004-01-13 US disclosed
WO-2003057674-A1 4-SULFIDE / SULFOXIDE / SULFONYL-1H-PYRAZOLYL DERIVATIVE COMPOUNDS, FOR USE IN DISEASES ASSOCIATED WITH THE 5-HT2C RECEPTOR BAYER PHARMACEUTICALS CORPORATION (US) 2003-07-17 WO disclosed
US-6589963-B2 Drug salt thereof show a hypoglycemic action, a blood hypolipidemic action, an insulin resistance-improving action and a PPAR activating action, and are useful as a hypoglycemic agent, a hypolipidemic agent, an insulin KYOTO PHARMACEUTICAL INDUSTRIES, LTD. (JP) 2003-07-08 US disclosed
US-20030027836-A1 Novel heterocyclic compounds and salts thereof and medicinal use of the same KYOTO PHARMACEUTICAL INDUSTRIES, LTD. (JP) 2003-02-06 US disclosed
EP-1236719-A1 NOVEL HETEROCYCLIC COMPOUNDS AND SALTS THEREOF AND MEDICINAL USE OF THE SAME Kyoto Pharmaceutical Industries, Ltd. (JP) 2002-09-04 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12378249-B2 Isoquinoline compounds and uses thereof HIPK1, HPGDS, IP6K1 KDM4E 1953/4885USP2 1365/4885ALDH1A1 3680/4885
US-20260034140-A1 MODULATORS OF RHO-ASSOCIATED PROTEIN KINASE ROCK1, ROCK2, RHOA KDM4E 1773/4885USP2 2859/4885ALDH1A1 4825/4885
US-12453734-B2 Modulators of rho-associated protein kinase ROCK2, ROCK1, RHOA KDM4E 1568/4885USP2 2567/4885ALDH1A1 4441/4885
US-20240216386-A1 MODULATORS OF RHO-ASSOCIATED PROTEIN KINASE ROCK2, ROCK1, RHOA KDM4E 1568/4885USP2 2567/4885ALDH1A1 4441/4885
US-20030027836-A1 Novel heterocyclic compounds and salts thereof and medicinal use of the same GPR119, PPARA, PPARG KDM4E 2688/4885USP2 4547/4885ALDH1A1 1921/4885
US-20040152712-A1 Pharmaceutically active compounds PDE5A, PDE3A, PDE2A KDM4E 1524/4885USP2 4353/4885ALDH1A1 507/4885
US-20050119489-A1 4-Sulfide/sulfoxide/sulfonyl-1h-pyrazolyl derivative compounds, for use in diseases associated with the 5-ht2c receptor HTR2C, HTR2A, HTR2B KDM4E 2840/4885USP2 2506/4885ALDH1A1 813/4885
US-12281119-B2 Imidazo[2,1-f][1,2,4]triazin-4-amine derivatives as TLR7 agonist TLR7, TLR1, TLR3 KDM4E 2575/4885USP2 3768/4885ALDH1A1 1611/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.